US4083974A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
Assignee: Pharmacia and Upjohn Co
•
Filing: 1977-03-07
•
Granted: 1978-04-11
•
Expires: 1997-03-07
Abstract
Abstract The present invention discloses topical preparations containing anti-inflammatory steroids. These may be ointments or solutions which contain as a solubilizing agent for the steroid, polyoxypropylene 15 stearyl ether.
Inventors
- 👤 Joseph S. Turi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 13:11
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61K31/58; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K9/00; A61K9/0012; A61K9/0014
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
53 words
A pharmaceutical composition in ointment form for topical application which comprises an anti-inflammatory effective amount of an anti-inflammatory steroid selected from the group consisting of diflorasone diacetate, betamethasone valerate fluocinonide, clobetasol propionate, methylprednisolone acetate, fluorometholone, fluocinolone acetonide, hydrocortisone acetate, fludrocortisone, flumethasone and triamcinolone acetonide and 1 thru 40% of polyoxypropylene 15 stearyl ether.
Claim 2
Dependent Claim
53 words
A pharmaceutical composition in ointment form for topical application which comprises an anti-inflammatory effective amount of an anti-inflammatory steroid selected from the group consisting of diflorasone diacetate, betamethasone valerate fluocinonide, clobetasol propionate, methylprednisolone acetate, fluorometholone, fluocinolone acetonide, hydrocortisone acetate, fludrocortisone, flumethasone and triamcinolone acetonide and 1 thru 40% of polyoxypropylene 15 stearyl ether.
Claim 3
Dependent Claim
19 words
A pharmaceutical composition according to claim 1 where the polyoxypropylene 15 stearyl ether is present in 15 thru 40%.
Claim 4
Dependent Claim
14 words
A pharmaceutical composition according to claim 2 where the anti-inflammatory steroid is diflorasone diacetate.
Claim 5
Dependent Claim
17 words
A pharmaceutical composition according to claim 3 where the anti-inflammatory effective amount of diflorasone diacetate is 0.01-0.1%.
Claim 6
Dependent Claim
14 words
A pharmaceutical composition according to claim 2 where the anti-inflammatory steroid is betamethasone valerate.
Claim 7
Dependent Claim
13 words
A pharmaceutical composition according to claim 2 where the anti-inflammatory steroid is fluocinonide.
Claim 8
Dependent Claim
14 words
A pharmaceutical composition according to claim 2 where the anti-inflammatory steroid is fluocinolone acetonide.
Claim 9
Dependent Claim
14 words
A pharmaceutical composition according to claim 2 where the anti-inflammatory steroid is clobetasol propionate.
Claim 10
Dependent Claim
55 words
A pharmaceutical composition in nonaqueous solution form for topical application which comprises an anti-inflammatory effective amount of an anti-inflammatory steroid selected from the group consisting of diflorasone diacetate, betamethasone valerate, fluocinonide, clobetasol propionate, methylprednisolone acetate, fluorometholone, fluocinolone acetonide, hydrocortisone acetate, fludrocortisone, flumethasone and triamcinolone acetonide and a solubilizing effective amount of polyoxypropylene 15 stearyl ether.
Claim 11
Dependent Claim
55 words
A pharmaceutical composition in nonaqueous solution form for topical application which comprises an anti-inflammatory effective amount of an anti-inflammatory steroid selected from the group consisting of diflorasone diacetate, betamethasone valerate, fluocinonide, clobetasol propionate, methylprednisolone acetate, fluorometholone, fluocinolone acetonide, hydrocortisone acetate, fludrocortisone, flumethasone and triamcinolone acetonide and a solubilizing effective amount of polyoxypropylene 15 stearyl ether.
Claim 12
Dependent Claim
14 words
A pharmaceutical composition according to claim 9 where the anti-inflammatory steroid is diflorasone diacetate.
Claim 13
Dependent Claim
21 words
A pharmaceutical composition in ointment form comprising 0.01-0.1% of diflorasone diacetate, 1-40% of polyoxypropylene 15 stearyl ether and pharmaceutically acceptable carriers.
Claim 14
Dependent Claim
21 words
A pharmaceutical composition in ointment form comprising 0.01-0.1% of diflorasone diacetate, 1-40% of polyoxypropylene 15 stearyl ether and pharmaceutically acceptable carriers.
Claim 15
Dependent Claim
29 words
A pharmaceutical composition in ointment form comprising ______________________________________
Ingredient %
______________________________________
Diflorasone diacetate
0.01-0.10
Polyoxypropylene 15
stearyl ether 5-30
Stearic acid 5-20
Multi-sterol extract 5-30
White petrolatum 20-85
______________________________________
Claim 16
Dependent Claim
29 words
A pharmaceutical composition in ointment form comprising ______________________________________
Ingredient %
______________________________________
Diflorasone diacetate
0.01-0.10
Polyoxypropylene 15
stearyl ether 5-30
Stearic acid 5-20
Multi-sterol extract 5-30
White petrolatum 20-85
______________________________________
Claim 17
Dependent Claim
31 words
A pharmaceutical composition in ointment form comprising ______________________________________
Ingredient %
______________________________________
Diflorasone diacetate
0.05
Polyoxypropylene 15
stearyl ether 15.00
Stearic acid U.S.P. 15.00
Multi-sterol extract 10.00
White petrolatum U.S.P.
59.95
______________________________________
Claim 18
Dependent Claim
31 words
A pharmaceutical composition in ointment form comprising ______________________________________
Ingredient %
______________________________________
Diflorasone diacetate
0.05
Polyoxypropylene 15
stearyl ether 15.00
Stearic acid U.S.P. 15.00
Multi-sterol extract 10.00
White petrolatum U.S.P.
59.95
______________________________________
References Cited (Backward Citations)
US4017615A
Cited
US3981996A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-04-10 | 1981-10-10 | 1982-04-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-04-10 | 1985-10-10 | 1986-04-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-04-10 | 1989-10-10 | 1990-04-11 | $7700.00 | Window Closed / Lapsed |